Back
Varonis Systems 10K Form
Buy
68
VRNS
Varonis Systems
Last Price:
$45.73
Seasonality Move:
12.46%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-07 | 10Q | VRNS/Varonis Systems Quarterly |
| 2023-10-31 | 10Q | VRNS/Varonis Systems Quarterly |
| 2023-08-01 | 10Q | VRNS/Varonis Systems Quarterly |
| 2023-05-02 | 10Q | VRNS/Varonis Systems Quarterly |
| 2022-11-01 | 10Q | VRNS/Varonis Systems Quarterly |
| 2022-08-02 | 10Q | VRNS/Varonis Systems Quarterly |
Receive VRNS News And Ratings
See the #1 stock for the next 7 days that we like better than VRNS
VRNS Financial Statistics
Sales & Book Value
| Annual Sales: | $551M |
|---|---|
| Cash Flow: | $65.3M |
| Price / Cash Flow: | 46.53 |
| Annual Sales: | $3.26 |
| Price / Book: | 13.96 |
Profitability
| EPS (TTM): | -0.81000 |
|---|---|
| Net Income (TTM): | $-91.1M |
| Gross Margin: | $457.1M |
| Return on Equity: | -21.05% |
| Return on Assets: | -6.59% |
Varonis Systems Earnings Forecast
Key Varonis Systems Financial Ratios
-
The Gross Profit Margin over the past 15 years for VRNS is 82.97%.
-
The Selling, General & Administrative Expenses for VRNS have been equal to 68.61% of Gross Profit Margin.
-
The Research & Development expenses have been 35.71% of Revenue.
-
The Net Earning history of VRNS is -17.38% of Total Revenues.
-
Per Share Earnings over the last 15 years have been positive in 5 years.
Varonis Systems Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Software |
| Sector: | Information Technology |
| Current Symbol: | VRNS |
| CUSIP: | 922280 |
| Website: | varonis.com |
Debt
| Debt-to-Equity Ratio: | 1.91 |
|---|---|
| Current Ratio: | 1.15 |
| Quick Ratio: | 1.03 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 119.7 |
VRNS Technical Analysis vs Fundamental Analysis
Buy
68
Varonis Systems (VRNS)
is a Buy
Is Varonis Systems a Buy or a Sell?
-
Varonis Systems stock is rated a BuyThe current Varonis Systems [VRNS] share price is $45.88. The Score for VRNS is 68, which is 36% above its historic median score of 50, and infers lower risk than normal.